CRESCENT BIOPHARMA, INC. Accrued Liabilities, Current
CRESCENT BIOPHARMA, INC. (CBIO) had Accrued Liabilities, Current of $7.41 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-07-30
- 2026-06-30: Accrued Liabilities, Current $7.41M.
- 2026-03-31: Accrued Liabilities, Current $4.43M.
- 2025-12-31: Accrued Liabilities, Current $16.34M.
- 2025-09-30: Accrued Liabilities, Current $8.96M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $7.41M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $4.43M 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $16.34M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $8.96M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $7.61M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $2.51M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $2.23M 10-K · filed 2026-02-26 | $5.38M 10-K · filed 2025-02-13 |
| 2024-09-30 | $3.48M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $2.96M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $3.91M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $5.23M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $5.31M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $5.51M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $5.61M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $6.99M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $5.81M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $6.61M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $9.48M 10-Q · filed 2022-04-28 | |
| 2021-12-31 | $8.72M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $7.30M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $8.13M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $7.78M 10-Q · filed 2021-05-03 | |
| 2020-12-31 | $9.44M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $7.87M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $7.48M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $6.65M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $8.71M 10-K · filed 2021-03-02 | |
| 2019-09-30 | $6.60M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $5.76M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $5.18M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $6.00M 10-K · filed 2020-02-28 | $4.27M 10-K · filed 2019-03-06 |
| 2018-09-30 | $4.39M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $2.86M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $4.32M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $3.57M 10-K · filed 2019-03-06 | |
| 2017-09-30 | $3.68M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $4.03M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $3.56M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $3.27M 10-K · filed 2018-03-06 | |
| 2016-09-30 | $3.26M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $4.06M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $3.78M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $6.15M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $5.52M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $5.20M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $2.63M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $4.74M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $3.45M 10-Q · filed 2014-10-31 | |
| 2014-06-30 | $2.64M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $559.96K 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $685.75K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |